Retinopathy of Prematurity (ROP) Market to Hit USD 1.7 Billion by 2034

Retinopathy of prematurity (ROP) is a potentially blinding eye disorder that primarily affects premature infants with low birth weight. It is caused by abnormal retinal blood vessel development, which may progress to retinal detachment if untreated.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72279

With advances in neonatal intensive care units (NICUs), survival rates of premature infants have improved worldwide - but this has also led to a higher incidence of ROP. The market is expanding with the growing use of anti-VEGF agents, laser photocoagulation, and tele-ophthalmology screening, as well as research into long-acting biologics and gene therapy for retinal diseases.

Market Overview
• Market Size (2024): USD 786 million
• Forecast (2034): USD 1.7 billion
• CAGR (2025-2034): 8.0%

Key Highlights:
• Rising global premature birth rates fueling ROP prevalence.
• Increasing adoption of anti-VEGF injections (ranibizumab, bevacizumab, aflibercept).
• Laser photocoagulation remains widely used but biologics are rapidly gaining share.
• Growing role of AI-powered tele-retinal screening in NICUs.

Segmentation Analysis
By Treatment Type:
• Laser Photocoagulation (standard therapy, cost-effective)
• Anti-VEGF Therapies
o Bevacizumab (off-label)
o Ranibizumab
o Aflibercept

• Combination Therapy (laser + anti-VEGF)
• Adjunctive/Supportive Care (oxygen management, monitoring)
• Emerging Therapies (gene therapy, regenerative medicine)

By Stage of Disease:
• Mild ROP (observation/monitoring)
• Moderate ROP (anti-VEGF or laser therapy)
• Severe ROP (combination therapy, surgery for retinal detachment)

By End Use:
• Hospitals & NICUs
• Specialty Eye Clinics
• Tele-ophthalmology & Screening Programs
• Academic & Research Institutes

Segmentation Summary:
Laser therapy remains the mainstay of ROP management, but anti-VEGF agents are the fastest-growing treatment segment, offering precision and reduced collateral damage.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72279/retinopathy-of-prematurity-market

Regional Analysis
North America
• Largest market (~41% share in 2024).
• High NICU survival rates increasing ROP cases.
• Strong adoption of anti-VEGF biologics and AI-based screening.
Europe
• ~30% share.
• Germany, UK, and France lead in NICU-based ROP care.
• EMA approvals supporting biologic adoption.
Asia-Pacific
• Fastest-growing region, CAGR ~9.2%.
• Largest premature birth rates globally, especially in India and China.
• Rising demand for tele-ophthalmology programs to address rural patient populations.
Latin America
• Brazil and Mexico expanding ROP screening and treatment infrastructure.
Middle East & Africa
• GCC countries improving neonatal care facilities.
• High unmet need in African nations due to limited NICU and ophthalmology capacity.
Regional Summary:
North America and Europe lead adoption today, but Asia-Pacific will drive fastest growth, given its high premature birth rates and increasing access to advanced therapies.

Market Dynamics
Key Growth Drivers:
• Rising premature birth rates worldwide.
• Expanding access to anti-VEGF therapies and advanced NICUs.
• Growing use of AI-driven tele-ophthalmology for ROP screening.
• Strong pipeline of next-generation biologics and regenerative treatments.

Key Challenges:
• Limited awareness and screening access in low-income regions.
• High treatment costs of anti-VEGF biologics.
• Risk of systemic side effects in neonates from intravitreal injections.
• Shortage of pediatric retina specialists in many countries.

Latest Trends:
• Development of long-acting anti-VEGF formulations for infants.
• AI-based predictive models for ROP progression risk.
• Growing integration of telemedicine in NICUs.
• Clinical trials in gene therapy and regenerative medicine for retinal vascular repair.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72279

Competitor Analysis
Major Players in the Market:
• Novartis AG (Lucentis - ranibizumab)
• Regeneron Pharmaceuticals, Inc. (Eylea - aflibercept)
• Roche Holding AG (faricimab pipeline)
• Bayer AG
• Pfizer Inc.
• Bausch + Lomb
• Santen Pharmaceutical Co., Ltd.
• Allergan (AbbVie Inc.)
• Eyepoint Pharmaceuticals, Inc.
• Academic and biotech startups advancing neonatal retina research

Competitive Summary:
Novartis and Regeneron dominate anti-VEGF therapies for ROP, while Roche is advancing dual-pathway biologics. Bausch and Santen provide ophthalmic support solutions, while biotech innovators explore long-acting biologics and gene therapy approaches.

Conclusion
The Retinopathy of Prematurity (ROP) Market, valued at USD 786 million in 2024, is projected to reach USD 1.7 billion by 2034, growing at a CAGR of 8.0%.

Key Takeaways:
• Premature birth trends drive the global ROP burden.
• Laser therapy dominates today, but anti-VEGF agents are growing fastest.
• North America and Europe lead adoption, while Asia-Pacific experiences the highest growth.
• AI-based tele-screening, long-acting biologics, and gene therapy represent the future of ROP management.

Over the next decade, the ROP market will shift toward precision biologics, AI-driven early detection, and regenerative approaches, significantly improving vision outcomes for premature infants worldwide.

This report is also available in the following languages : Japanese (未熟児網膜症市場), Korean (미숙아 망막병증 시장), Chinese (早产儿视网膜病变市场), French (Marché de la rétinopathie du prématuré), German (Markt für Frühgeborenen-Retinopathie), and Italian (Mercato della retinopatia del prematuro), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72279/retinopathy-of-prematurity-market#request-a-sample

Our More Reports:

Glycan Analysis Market
https://exactitudeconsultancy.com/reports/72860/glycan-analysis-market

CRISPR Gene Editing Therapies Market
https://exactitudeconsultancy.com/reports/72861/crispr-gene-editing-therapies-market

Drug Discovery Platforms Market
https://exactitudeconsultancy.com/reports/72862/drug-discovery-platforms-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.